The potential benefit of stem cell therapy after stroke: an update
Soma Banerjee,1 Deborah A Williamson,2 Nagy Habib,3 Jeremy Chataway4,5
1Department of Stroke Medicine, Imperial College Healthcare NHS Trust, London, UK; 2Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand; 3Department of Surgery, Imperial College London, London, UK; 4Clinical Neurosciences, Imperial College Healthcare NHS Trust, London, UK; 5National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK
Abstract: Stroke is a leading cause of death and disability worldwide. Stem cell therapy is an emerging therapeutic modality with evidence of significant benefits in preclinical stroke models. A number of phase I and II clinical trials have now been completed, with several more currently under way. Translation to the bedside, however, remains a long way off, and there are many questions that remain unanswered. This review will summarize the current evidence and ongoing clinical trials worldwide, and explore the challenges to making this a realistic treatment option for the future.
Keywords: stroke, stem cells, clinical trials
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]